Nanobiotix S.A. stock surges on promising cancer trial results and major partnership. Click for more on NBTX stock and why ...

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda® (pembrolizumab) alone (10.8 months) and Keytruda® + chemotherapy (12.3 months) in patients ...

In a recent annual report from the American Cancer Society, it said the statistics for prostate cancer is rising after the years of decline.

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

While some patients may view head and neck cancer screenings as an unnecessary optional screening, these exams can be ...

Half-Year Results and Business UpdatePositive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% ...

The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for ...

A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.

This guide for newly diagnosed patients provides key information to help you understand your options and have informed ...

Key Takeaways A new blood test can detect head and neck cancers years before symptoms appearThe test looks for DNA released ...

UPMC Hillman Cancer Center in Central Pennsylvania is offering Surface Guided Radiation Therapy to treat a variety of cancers ...